CN114957259A - Cyano-substituted aromatic bicyclic compound and application thereof - Google Patents
Cyano-substituted aromatic bicyclic compound and application thereof Download PDFInfo
- Publication number
- CN114957259A CN114957259A CN202210164876.4A CN202210164876A CN114957259A CN 114957259 A CN114957259 A CN 114957259A CN 202210164876 A CN202210164876 A CN 202210164876A CN 114957259 A CN114957259 A CN 114957259A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- compounds
- acceptable salt
- ros1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 aromatic bicyclic compound Chemical class 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 137
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 71
- 238000006243 chemical reaction Methods 0.000 description 49
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 37
- 239000000243 solution Substances 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 27
- 239000012043 crude product Substances 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 108091000080 Phosphotransferase Proteins 0.000 description 19
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 19
- 102000020233 phosphotransferase Human genes 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 239000012065 filter cake Substances 0.000 description 18
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 16
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 102220196513 rs1057519788 Human genes 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 101150111783 NTRK1 gene Proteins 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000012054 celltiter-glo Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- DORJQZDOULKINH-QNBGGDODSA-N 3-[4-[(2r)-2-aminopropoxy]phenyl]-n-[(1r)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine;hexanedioic acid Chemical compound OC(=O)CCCCC(O)=O.C1=CC(OC[C@H](N)C)=CC=C1C1=CN=C2N1N=C(N[C@H](C)C=1C=C(F)C=CC=1)C=C2 DORJQZDOULKINH-QNBGGDODSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 101150035397 Ros1 gene Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 4
- 229960005061 crizotinib Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- ASNVMKIDRJZXQZ-ZCFIWIBFSA-N (1r)-1-(3-fluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=CC(F)=C1 ASNVMKIDRJZXQZ-ZCFIWIBFSA-N 0.000 description 2
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical compound CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- SDGRJKAZYSMLMF-GDVGLLTNSA-N C(=O)(OC(C)(C)C)[C@@H]1C(=O)OCC1N Chemical compound C(=O)(OC(C)(C)C)[C@@H]1C(=O)OCC1N SDGRJKAZYSMLMF-GDVGLLTNSA-N 0.000 description 1
- ASVYXWZOBCRSFB-UHFFFAOYSA-N C(C)S(=O)(O)=S.OCCN1CCNCC1 Chemical compound C(C)S(=O)(O)=S.OCCN1CCNCC1 ASVYXWZOBCRSFB-UHFFFAOYSA-N 0.000 description 1
- MNCFZWFXTUZLEI-UHFFFAOYSA-N CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NC(N)COCCO Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NC(N)COCCO MNCFZWFXTUZLEI-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- ITQFPVUDTFABDH-AATRIKPKSA-N ethyl (e)-3-ethoxyprop-2-enoate Chemical compound CCO\C=C\C(=O)OCC ITQFPVUDTFABDH-AATRIKPKSA-N 0.000 description 1
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- FIKPXCOQUIZNHB-WDEREUQCSA-N repotrectinib Chemical compound C[C@H]1CNC(=O)C2=C3N=C(N[C@H](C)C4=C(O1)C=CC(F)=C4)C=CN3N=C2 FIKPXCOQUIZNHB-WDEREUQCSA-N 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Novel cyano-substituted aromatic bicyclic compounds and application thereof, in particular to compounds shown as a formula (III) and pharmaceutically acceptable salts thereof.
Description
The invention claims the following priority:
CN202110216147.4, application date: 25/02/2021;
CN202110683432.7, application date: 18 months 06 in 2021;
CN202111139972.5, application date: 09/27 days 2021.
Technical Field
The invention relates to a cyano-substituted aromatic bicyclic compound and application thereof, in particular to a compound shown as a formula (III) and pharmaceutically acceptable salts thereof.
Background
Protein kinase plays an important role in human body and is widely involved in the processes of proliferation, differentiation, metabolism, apoptosis and the like of various cells in the human body. Oncogenic forms of protein kinases are abundantly expressed in a variety of different human tumor types and are highly responsive to several specific kinase inhibitors. The c-ROS protooncogene 1receptor tyrosine kinase (ROS 1) belongs to the insulin receptor superfamily, and is widely involved in cell growth, proliferation and transformation by regulating main signal pathways such as RAS/MAPK, PI3K/AKT, STAT3 and the like, and possibly involved in the developmental and maturation process of organs. Abnormal expression of ROS1 kinase, such as point mutations, overexpression, and gene fusions, can cause dysregulated kinase activity and are associated with many human cancer types.
ROS1 fusion kinase loses the extracellular domain, retaining the transmembrane and intracellular tyrosine kinase domains. It is constitutively activated without ligand binding, induces tumorigenesis by phosphorylating substrate proteins and drives the survival and proliferation of tumor cells. The CD74-ROS1 gene fusion is found in NSCLC patients for the first time in 2007, and more than 14 chaperone genes have been identified so far. ROS1 gene fusion is another definite NSCLC driving gene after EGFR mutation and ALK fusion, and the positive incidence rate of east Asia population is about 2-3%, and the positive incidence rate of Europe and America is about 1-2%. In 2016, 3 months, FDA approved Crizotinib (Crizotinib) for the treatment of ROS1 gene fusion NSCLC based on data from only 50 patients (PROFILE 1001). Crizotinib was shown to be one of the major resistance mechanisms of crizotinib with a significant efficacy (objective response rate of 72%), but developed to resistance after about one year, with the acquired resistance mutation of ROS1 kinase (about 50-60%, approximately 40% of the solvent front mutation G2032R). However, no targeted drug is available for NSCLC patients with G2032R acquired resistance mutation at the ROS1 kinase solvent front. The preclinical data of the first three co-company on the study of the ROS1 inhibitor DS-6051b show that it has a good effect on the ROS1-G2032R solvent front resistance mutation, and clinical experiments are currently underway. However, DS-6051b is also a multi-kinase inhibitor (DS-6051b is also a strong pan-NTRK inhibitor at the same time) as all other clinical ROS1 inhibitors. Particularly, the ROS1 inhibitor Entrectinib (RXDX-101) and Reotretinib (TPX-0005) are strong pan-NTRK inhibitors, and the side effects of dysgeusia, dizziness, paresthesia, weight gain and the like are widely existed clinically, and the side effects are possibly related to off-target caused by strong inhibition of Trk kinase. For the patient only fused with the ROS1 gene, in addition to the target-related side effects, the side effects caused by off-target are also required to be borne, which can affect the treatment effect and the patient experience.
Therefore, for the clinical treatment of ROS1 gene fused NSCLC, a class of selective ROS1 inhibitors with low off-target side effects and effective against drug-resistant mutations currently on the market is urgently needed.
Disclosure of Invention
The invention provides a compound shown as a formula (II I) or a pharmaceutically acceptable salt thereof,
wherein the content of the first and second substances,
y and T are each independently selected from CH and N;
R 1 selected from F, Cl, Br, I, C 1-3 Alkyl radical, C 1-3 Alkoxy, pyrrolidinyl and-C 1-3 Alkoxy-pyrrolidinyl, said C 1-3 Alkyl radical, C 1-3 Alkoxy, pyrrolidinyl and-C 1-3 Alkoxy-pyrrolidinyl is optionally substituted with 1, 2 or 3R a Substitution;
R 2 selected from F, Cl, Br, I, OH and C 1-3 Alkyl radical, said C 1-3 Alkyl is optionally substituted by 1, 2 or 3R b Substitution;
m and n are each independently selected from 1 and 2;
l is selected from-C 1-3 Alkyl-, -N (R) c )-C 1-3 alkyl-and-O-C 1-3 Alkyl-;
ring a is selected from phenyl, pyridyl, pyrimidinyl, and pyrazinyl;
ring B is selected from phenyl and pyridyl;
R a independently selected from F, Cl, Br, I, OH, NH 2 、=O、C 1-3 Alkyl and C 1-3 An alkylamino group;
R b independently selected from F, Cl, Br, I, OH and NH 2 ;
R c Selected from H and C 1-3 An alkyl group.
In some embodiments of the present invention, R is a Independently selected from F, Cl, Br, I, OH, NH 2 、=O、CH 3 、CH(CH 3 ) 2 And N (CH) 3 ) 2 The other variables are as defined herein.
In some embodiments of the invention, R is as defined above 1 Selected from F, Cl, Br, I, CH 3 、OCH 3 、CH 2 CH 3 、OCH 2 CH 2 CH 3 、 The CH 3 、OCH 3 、CH 2 CH 3 、OCH 2 CH 2 CH 3 、Optionally substituted by 1, 2 or 3R a And the other variables are as defined herein.
In some embodiments of the invention, R is as defined above 1 Selected from F, Cl, Br, I, CH 3 、OCH 3 、CH 2 CH 3 、OCH 2 CH 2 CH 3 、 Other variables are as defined herein.
In some embodiments of the invention, the above-mentioned F, Cl, Br, I, CH 3 、OCH 3 、 Other variables are as defined herein.
In some embodiments of the invention, R is as defined above 1 Selected from F, Cl, Br, I, CH 3 、OCH 3 、 The other variables are as defined herein.
In some embodiments of the invention, R is as defined above 2 Selected from F, Cl, Br, I and CH 3 Said CH 3 Optionally substituted by 1, 2 or 3R b And the other variables are as defined herein.
In some embodiments of the invention, R is as defined above 2 Selected from F, Cl, Br, I, CH 3 And CF 3 And the other variables are as defined herein.
In some embodiments of the invention, L is selected from-CH 2 -、-CH 2 CH 2 -、-NH-CH 2 -、-NH-CH(CH 3 ) and-O-CH 2 The other variables are as defined herein.
In some embodiments of the present invention, the structural unitIs selected fromOther variables are as defined herein.
In some embodiments of the invention, the structural unitIs selected fromOther variables are as defined herein.
In some embodiments of the present invention, the structural unit is a structural unitIs selected from Other variables are as defined herein.
The invention provides a compound shown as a formula (I) or a pharmaceutically acceptable salt thereof,
wherein the content of the first and second substances,
R 1 selected from H, F, Cl, Br, I, C 1-3 Alkyl radical, C 1-3 Alkoxy andsaid C is 1-3 Alkyl radical, C 1-3 Alkoxy andoptionally substituted by 1, 2 or 3R a Substitution;
R 2 selected from H, F, Cl, Br, I, OH and C 1-3 Alkyl radical, said C 1-3 Alkyl is optionally substituted by 1, 2 or 3R b Substitution;
m and n are each independently selected from 0, 1 and 2;
l is selected from-C 1-3 Alkyl-, -N (R) c )-C 1-3 alkyl-and-O-C 1-3 Alkyl-;
ring B is selected from phenyl and pyridyl;
R a and R b Each independently selected from F, Cl, Br, I, OH and NH 2 ;
R c Selected from H and C 1-3 An alkyl group.
In some embodiments of the invention, R is as defined above 1 Selected from H, F, Cl, Br, I, CH 3 、OCH 3 、CH 2 CH 3 、OCH 2 CH 2 CH 3 Andthe CH 3 、OCH 3 、CH 2 CH 3 、OCH 2 CH 2 CH 3 Andoptionally substituted by 1, 2 or 3R a And the other variables are as defined herein.
In some embodiments of the invention, R is as defined above 1 Selected from H, F, Cl, Br, I, CH 3 、OCH 3 、CH 2 CH 3 、OCH 2 CH 2 CH 3 、 The other variables are as defined herein.
In some embodiments of the present invention, R is 1 Is selected fromOther variables are as defined herein.
In some embodiments of the invention, R is as defined above 2 Selected from H, F, Cl, Br, I and CH 3 Said CH 3 Optionally substituted by 1, 2 or 3R b And the other variables are as defined herein.
In some embodiments of the invention, R is as defined above 2 Selected from H, F, Cl, Br, I, CH 3 And CF 3 The other variables are as defined herein.
In some embodiments of the invention, L is selected from-CH 2 -、-CH 2 CH 2 -、-NH-CH 2 -、-NH-CH(CH 3 ) and-O-CH 2 The other variables are as defined herein.
In the inventionIn some embodiments, the structural unitIs selected fromOther variables are as defined herein.
In some embodiments of the invention, the structural unitIs selected fromOther variables are as defined herein.
Further aspects of the invention are derived from any combination of the above variables.
In some embodiments of the invention, the compound, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:
wherein the content of the first and second substances,
R 1 、R 2 l, m and n are as defined herein.
Further aspects of the invention are derived from any combination of the above variables.
In some embodiments of the invention, the compound, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:
wherein the content of the first and second substances,
R 1 and R 2 As defined herein.
The invention also provides a compound shown as the following formula or a pharmaceutically acceptable salt thereof,
in some embodiments of the invention, the compound, or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:
technical effects
The compound shows higher kinase inhibition activity in ROS1 kinase and mutant ROS1-G2032R thereof, and the activity is equivalent to that of DS-6051 b; but the compound of the invention has weaker inhibitory activity on TrkA kinase, and respectively shows 560-fold and 1680-fold kinase selectivity which is obviously superior to DS-6051 b; the compound shows higher cell proliferation inhibition activity on ROS1 mutant cell strains Ba/F3 SLC34A2-ROS1-G2032R and Ba/F3 CD74-ROS1-G2032R, but shows lower cell proliferation inhibition activity on cell strains Ba/F3-LMNA-NTRK1, and the selectivity of the compound is obviously superior to that of DS-6051 b; the compounds of the present invention exhibit superior pharmacokinetic properties.
Definitions and explanations
As used herein, the following terms and phrases are intended to have the following meanings, unless otherwise indicated. A particular term or phrase, unless specifically defined, should not be considered as indefinite or unclear, but rather construed according to ordinary meaning. When a trade name appears herein, it is intended to refer to its corresponding commodity or its active ingredient.
The term "pharmaceutically acceptable" as used herein is intended to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The term "pharmaceutically acceptable salts" refers to salts of the compounds of the present invention, prepared from the compounds of the present invention found to have particular substituents, with relatively nontoxic acids or bases. When compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting such compounds with a sufficient amount of a base in neat solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amines or magnesium salts or similar salts. When compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting such compounds with a sufficient amount of acid, either in neat solution or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, and the like; and salts of organic acids including acids such as acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-toluenesulfonic, citric, tartaric, methanesulfonic, and the like; also included are salts of amino acids such as arginine and the like, and salts of organic acids such as glucuronic acid and the like. Certain specific compounds of the invention contain both basic and acidic functionalities and can thus be converted to either base or acid addition salts.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound, which contains an acid or base, by conventional chemical methods. In general, such salts are prepared by the following method: prepared by reacting these compounds in free acid or base form with a stoichiometric amount of the appropriate base or acid, in water or an organic solvent or a mixture of the two.
Unless otherwise indicated, the term "isomer" is intended to include geometric isomers, cis-trans isomers, stereoisomers, enantiomers, optical isomers, diastereomers and tautomers.
The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-) -and (+) -enantiomers, (R) -and (S) -enantiomers, diastereomers, (D) -isomers, (L) -isomers, as well as racemic and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are included within the scope of the present invention.
Unless otherwise indicated, the terms "enantiomer" or "optical isomer" refer to stereoisomers that are mirror images of each other.
Unless otherwise indicated, the term "cis-trans isomer" or "geometric isomer" results from the inability of a double bond or a single bond to rotate freely within a ring-forming carbon atom.
Unless otherwise indicated, the term "diastereomer" refers to a stereoisomer in which the molecules have two or more chiral centers and a non-mirror image relationship between the molecules.
Unless otherwise indicated, "(+)" means dextrorotation, "(-) -means levorotation," (±) "means racemization.
Using solid wedge keys, unless otherwise indicatedAnd wedge dotted bondShowing the absolute configuration of a solid centre, by means of straight solid keysAnd straight dotted line bondShowing the relative configuration of the centres of solids, by wavy linesRepresenting solid-line keys of wedge shapeOr wedge dotted bondOr by wavy linesIndicating straight solid-line keysOr straight dotted line bond
Unless otherwise indicated, the terms "enriched in one isomer", "isomer enriched", "enantiomer enriched" or "enantiomeric enrichment" refer to a content of one isomer or enantiomer of less than 100%, and the content of the isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.
Unless otherwise indicated, the term "isomeric excess" or "enantiomeric excess" refers to the difference between the relative percentages of two isomers or enantiomers. For example, if the content of one isomer or enantiomer is 90%, and the content of the other isomer or enantiomer is 10%, the isomer or enantiomer excess (ee value) is 80%.
Optically active (R) -and (S) -isomers as well as D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the invention is desired, it may be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to afford the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (e.g., amino) or an acidic functional group (e.g., carboxyl), diastereomeric salts are formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and the pure enantiomers are recovered. Furthermore, separation of enantiomers and diastereomers is typically accomplished by using chromatography using a chiral stationary phase, optionally in combination with chemical derivatization (e.g., carbamate formation from amines).
The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be labelled with radioactive isotopes, such as tritium (A), (B), (C) and C) 3 H) Iodine-125 ( 125 I) Or C-14( 14 C) In that respect For example, deuterium can be used to replace hydrogen to form a deuterated drug, the bond formed by deuterium and carbon is stronger than the bond formed by common hydrogen and carbon, and compared with an undeuterated drug, the deuterated drug has the advantages of reducing toxic and side effects, increasing the stability of the drug, enhancing the curative effect, prolonging the biological half-life period of the drug and the like. All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
The terms "optional" or "optionally" mean that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
The term "substituted" means that any one or more hydrogen atoms on a particular atom is replaced with a substituent that may include deuterium and hydrogen variants, so long as the valency of the particular atom is normal and the substituted compound is stable. When the substituent is oxygen (i.e., ═ O), it means that two hydrogen atoms are substituted. Oxygen substitution does not occur on aromatic groups. The term "optionally substituted" means that it may or may not be substituted and, unless otherwise specified, the type and number of substituents may be arbitrary on the basis of chemical feasibility.
When any variable (e.g., R) occurs more than one time in the composition or structure of a compound, its definition in each case is independent. Thus, for example, if a group is substituted with 0-2R, the group may optionally be substituted with up to two R, and there are separate options for R in each case. Furthermore, combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
When the number of one linking group is 0, e.g., - (CRR) 0 -, represents that the linking group is a single bond.
When the number of a substituent is 0, it means that the substituent is absent, such as-A- (R) 0 Indicating that the structure is actually-a.
When a substituent is absent, it indicates that the substituent is absent, e.g., when X is absent in A-X, it indicates that the structure is actually A.
When one of the variables is selected from a single bond, it means that the two groups to which it is attached are directly connected, for example, where L represents a single bond in A-L-Z means that the structure is actually A-Z.
When a substituent bond can be cross-linked to more than two atoms of a ring, such substituent may be bonded to any atom of the ring, e.g. a building blockMeans that the substituent R can be substituted at any position on cyclohexyl or cyclohexadiene. When none of the listed substituents indicate through which atom it is attached to the substituted group, such substituent may be through any of its atomsThe atoms are bonded, for example, a pyridyl group as a substituent may be bonded to the substituted group through any one of the carbon atoms on the pyridyl ring.
When the listed linking groups do not indicate their direction of attachment, the direction of attachment is arbitrary, for example,wherein the linking group L is-M-W-, in which case-M-W-can be formed by connecting the ring A and the ring B in the same direction as the reading sequence from left to rightThe ring A and the ring B may be connected in the reverse direction of the reading sequence from left to rightCombinations of the linking groups, substituents, and/or variants thereof are permissible only if such combinations result in stable compounds.
Unless otherwise specified, when a group has one or more attachable sites, any one or more of the sites of the group may be attached to other groups by chemical bonds. When the chemical bond is not positioned and H atoms exist in the connectable sites, the number of the H atoms of the connectable sites is correspondingly reduced along with the number of the connected chemical bonds to become a group with corresponding valence number. The chemical bond between said site and other group may be a direct solid bondStraight dotted line keyOr wavy linesAnd (4) showing. For example-OCH 3 The straight solid line bond in (a) represents a bond to another group via an oxygen atom in the group;the straight dotted bond in (3) represents the linkage to the other group through both ends of the nitrogen atom in the group;the wavy line in (a) indicates that the phenyl group is bonded to other groups through the carbon atoms at the 1-and 2-positions in the phenyl group;means that any of the available attachment sites on the piperidinyl group can be attached to another group via 1 bond, including at leastThese 4 linkages, even though the-N-atom is depicted as H, areStill compriseThis attachment is a group whose H at the site is reduced by 1 to the corresponding monovalent piperidinyl group, except when 1 bond is attached.
Unless otherwise specified, the number of atoms on a ring is generally defined as the number of ring members, e.g., "5-7 membered ring" means a "ring" around which 5-7 atoms are arranged.
Unless otherwise specified, the term "C 1-3 Alkyl "is intended to mean a straight or branched saturated hydrocarbon group consisting of 1 to 3 carbon atoms. Said C is 1-3 The alkyl group comprising C 1-2 And C 2-3 Alkyl groups and the like; it may be monovalent (e.g., methyl), divalent (e.g., methylene), or multivalent (e.g., methine). C 1-3 Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
Unless otherwise specified, the term "C 1-3 Alkoxy "means that those containing 1 to 3 atoms linked to the rest of the molecule through an oxygen atomAlkyl groups of carbon atoms. Said C is 1-3 Alkoxy radicals comprising C 1-2 、C 2-3 、C 3 And C 2 Alkoxy, and the like. C 1-3 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.
Unless otherwise specified, the term "C 1-3 Alkylamino "refers to those alkyl groups containing 1 to 3 carbon atoms that are attached to the rest of the molecule through an amino group. Said C is 1-3 Alkylamino radicals comprising C 1-2 、C 3 And C 2 Alkylamino, and the like. C 1-3 Examples of alkylamino include, but are not limited to, -NHCH 3 、-N(CH 3 ) 2 、-NHCH 2 CH 3 、-N(CH 3 )CH 2 CH 3 、-NHCH 2 CH 2 CH 3 、-NHCH 2 (CH 3 ) 2 And so on.
The term "work-up" means that the formate, hydrochloride or trifluoroacetate salt of the compound of the present invention is obtained in the free state by dissolving in an organic solvent such as ethyl acetate, dichloromethane or methanol, washing with a 1N sodium bicarbonate solution and concentrating the organic phase.
The compounds of the present invention may be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combinations thereof with other chemical synthetic methods, and equivalents thereof known to those skilled in the art, with preferred embodiments including, but not limited to, examples of the present invention.
The compounds of the present invention may be structurally confirmed by conventional methods well known to those skilled in the art, and if the present invention relates to the absolute configuration of the compound, the absolute configuration may be confirmed by means of conventional techniques in the art. For example, single crystal X-ray diffraction method (SXRD), diffraction intensity data of the cultured single crystal is collected by a Bruker D8 venture diffractometer, a light source is CuK alpha radiation, and a scanning mode is as follows:scanning, collecting phasesAfter the data are closed, the crystal structure is further analyzed by a direct method (Shelxs97), so that the absolute configuration can be confirmed.
The solvent used in the present invention can be commercially available.
The invention employs the following abbreviations: aq represents water; eq represents equivalent, equivalent; DCM represents dichloromethane; PE represents petroleum ether; DMSO represents dimethyl sulfoxide; EtOAc for ethyl acetate; EtOH stands for ethanol; MeOH represents methanol; BOC represents tert-butoxycarbonyl as an amine protecting group; r.t. represents room temperature; O/N stands for overnight; THF represents tetrahydrofuran; boc 2 O represents di-tert-butyl dicarbonate; TFA represents trifluoroacetic acid; HCl represents hydrochloric acid; mp represents melting point; NBS stands for N-bromosuccinimide.
Detailed Description
The present invention is described in detail below by way of examples, but is not meant to be limited in any way. Having described the invention in detail and having disclosed specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
Reference example 1: synthesis of intermediate A-1
Step 1: synthesis of Compound A-1-2
A-1-1(5.2g,30.06mmol,1eq) and (R) -tert-butyl- (1-hydroxypropan-2-yl) aminomethyl ester (10.00g,57.07mmol,1.90eq) were dissolved in tetrahydrofuran (100mL) and then a solution of triphenylphosphine (8.92g,34.01mmol,1.13eq) and diisopropyl azodicarboxylate (8.01g,39.60mmol,7.70mL,1.32eq) in tetrahydrofuran (20mL) was added,the reaction solution was heated to 66 ℃ and stirred for 1 hour. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate: 100:0 to 5:1) to obtain compound a-1-2. 1 HNMR(400MHz,CDCl 3 )δ7.40-7.36(m,2H),6.82-6.77(m,2H),4.10-3.99(m,1H),3.90(d,J=4.0Hz,2H),1.46(s,9H),1.29(d,J=6.8Hz,3H)。
Step 2: synthesis of Compound A-1
Dissolving Compound A-1-2(4.85g,14.69mmol,1eq) in dioxane (50mL), adding the pinacol borate bis (4.11g,16.18mmol,1.10eq), potassium acetate (5.77g,58.78mmol,4.00eq), displacing with nitrogen and adding [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (1.20g,1.47mmol) was stirred at 80 ℃ for 1 hour under nitrogen atmosphere. After cooling to room temperature, 60mL of ethyl acetate was added to the reaction mixture, the reaction mixture was filtered under reduced pressure through a funnel with celite, the filter cake was washed twice with ethyl acetate (50mL), and the filtrate was concentrated in vacuo to give the crude product. And (3) separating and purifying the crude product by silica gel column chromatography (petroleum ether: ethyl acetate: 100: 0-3: 1) to obtain the compound A-1. 1 H NMR(400MHz,CDCl 3 )δ7.75(d,J=8.4Hz,2H),6.90(d,J=8.4Hz,2H),4.79(br s,1H),4.07(br s,1H),3.99-3.92(m,2H),1.46(s,9H),1.34(s,12H),1.28(d,J=7.2Hz,3H)。
Compound A-2 was synthesized according to the synthetic procedure of reference example 1, replacing (R) -tert-butyl- (1-hydroxypropan-2-yl) aminomethyl ester in step 1 with the fragments shown in the following Table, respectively. The crude product is not purified, and the reaction solution is directly used for the next reaction after vacuum concentration.
Compounds A-3, A-4, A-5, A-6 and A-7 were synthesized according to the synthesis procedure of reference example 1, substituting A-1-1 in step 1 with fragments shown in the following Table, respectively. The crude product is not purified, and the reaction solution is directly used for the next reaction after vacuum concentration.
Reference example 8: synthesis of intermediate A-8
Step 1: synthesis of Compound A-8-2
Dissolving compound a-8-1(200mg,1.16mmol,1eq) in dichloromethane (10mL) to this solution was added trimethylaluminum (2M,581.32uL,1eq) and the mixture was stirred at room temperature 15 ℃ for 15 minutes. (S) -Boc-3-amino-gamma-butyrolactone (236.28mg,1.17mmol, 1.01eq) was added to the reaction solution and the mixture was stirred at room temperature 15 ℃ overnight for 16 h. 50mL of water was added to the reaction solution, which was extracted with ethyl acetate (100 mL). Filtering the water phase through kieselguhr, extracting the filtrate for three times by 100mL each time with dichloromethane, combining all organic phases, drying through anhydrous sodium sulfate, concentrating under reduced pressure at 45 ℃ to obtain a crude product, and separating and purifying the crude product through silica gel column chromatography (petroleum ether: ethyl acetate ═ 1: 0-0: 1) to obtain the compound A-8-2. LCMS M/z 274.7[ M-100 ═] + 。
And 2, step: synthesis of Compound A-8-3
Compound A-8-2(1g,2.68mmol,1eq) was dissolved in tetrahydrofuran (50mL), di-tert-butyl azodicarboxylate (2.22g,9.65mmol,3.6eq) and tributylphosphine (1.95g,9.65mmol,2.38mL,3.6eq) were added to the solution, and the mixture solution was stirred at 70 ℃ for 16 hours. The reaction solution was concentrated in vacuo at 45 ℃, and then separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate: 1:0 to 1:1) to obtain compound a-8-3. The crude product was used in the next reaction without purification. LCMS M/z 356.0[ M +1 ]] + 。
And step 3: synthesis of Compound A-8
Dissolving the compound A-8-3(100mg,281.51umol,1eq) in 1, 4-dioxane (5mL), and adding the pinacol borate (78.63mg,309.66umol,1.1eq), [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (22.99mg,28.15umol,0.1eq)), nitrogen substituted, potassium acetate (110.51mg,1.13mmol,4eq) addedThe reaction was stirred at 80 ℃ for 16 hours under an atmosphere. The reaction solution was concentrated in vacuo to give compound A-8. The crude product was used in the next reaction without purification. LCMS M/z 403.2[ M +1 ]] + 。
Example 1
Step 1: synthesis of Compound 1-2
Compound 1-1(10g,77.19mmol,1eq) and sodium bicarbonate (9.73g,115.79mmol,4.50mL,1.5eq) were dissolved in dioxane (200mL), ethyl 3-bromopyruvate (18.06g,92.63mmol,11.58mL,1.2eq) was added, and the reaction was stirred at 100 ℃ for 16 hours. After the reaction solution was cooled to room temperature, the reaction solution was poured into water (500mL), stirred, and filtered to obtain a filter cake, the filter cake was washed three times with water (200mL each), then washed twice with n-pentane (200mL each), and the filter cake was vacuum-dried to obtain compound 1-2. 1 H NMR(400MHz,CDCl 3 )δ8.46(s,1H),7.98(d,J=9.6Hz,1H),7.15(d,J=9.6Hz,1H),4.48(q,J=7.2Hz,2H),1.45(t,J=7.2Hz,3H);LCMS m/z=225.8[M+1] + 。
Step 2: synthesis of Compounds 1-3
Compound 1-2(5g,22.16mmol,1eq) was dissolved in methanol (50mL), aqueous ammonia (92.19g,736.52mmol,101.30mL, 28% purity) was added, and the reaction was stirred at room temperature (18 ℃ C.) for 16 hours. And (3) concentrating the reaction solution in vacuum to remove methanol, filtering to obtain a filter cake, and drying the filter cake in vacuum to obtain the compound 1-3. LCMS M/z 196.8[ M +1 ═] + 。
And step 3: synthesis of Compounds 1-4
Compounds 1-3(2.57g,13.07mmol,1eq) and NBS (2.33g,13.07mmol,1eq) were dissolved in N, N-dimethylformamide (20mL) and stirred at room temperature (18 ℃ C.) for 16 hours. The reaction was filtered directly, the filter cake was washed three times with dichloromethane (20mL each), the filter cake was collected and dried under vacuum to give compounds 1-4. 1 H NMR(400MHz,CDCl 3 )δ7.89(d,J=9.2Hz,1H),7.23(d,J=9.6Hz,1H);LCMS m/z=276.7[M+1] + 。
And 4, step 4: synthesis of Compounds 1-5
Compound 1-4(2.58g,9.37mmol,1eq) was dissolved in pyridine (5mL), trifluoroacetic anhydride (2.99g,14.24mmol,1.98mL,1.52eq) was added at 10 ℃ and after stirring for 30 minutes, the reaction was raised to 18 ℃ and stirring was continued for 1.5 hours. And pouring the reaction solution into water (200mL), stirring, adjusting the pH value to 1-2, separating out solids, filtering, washing a filter cake with water for three times (50mL each time), and drying the filter cake in vacuum to obtain the compound 1-5. 1 H NMR(400MHz,DMSO-d 6 )δ8.39(d,J=9.6Hz,1H),7.68(d,J=9.6Hz,1H);LCMS m/z=258.7[M+1] + 。
And 5: synthesis of Compounds 1-6
Compounds 1 to 5(500mg,1.94mmol,1eq) and potassium fluoride (229.40mg,3.95mmol, 92.50. mu.L, 2.03eq) were dissolved in dimethyl sulfoxide (5mL), and (R) -1- (3-fluorophenyl) ethylamine (348.63mg,2.51mmol,1.29eq) was added and the reaction was stirred at 130 ℃ for 16 hours. After cooling to room temperature, the reaction solution was poured into water (200mL), ethyl acetate (300mL) was added, the mixture was stirred for 5 minutes, the layers were separated, and the aqueous layer was extracted three times with 300mL portions of ethyl acetate. The combined organic phases were washed with saturated aqueous sodium chloride (200mL), dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated in vacuo to give the crude product. And (3) purifying the crude product by silica gel column chromatography (ethyl acetate: petroleum ether ═ 0: 100-100: 0) to obtain a compound 1-6. LCMS M/z 359.8[ M + H [ ]] + .
Step 6: synthesis of Compounds 1-7
Compounds 1-6(0.1g, 277.64. mu. mol,1eq) and Compound A-1(106.84mg, 283.19. mu. mol,1.02eq) were dissolved in dioxane (0.4mL) and water (2mL), potassium carbonate (150.5mg,1.09mmol,3.92eq) was added, nitrogen was replaced, and [1,1' -bis (diphenylphosphino) ferrocene was added]Palladium dichloride dichloromethane complex (22.17mg) was reacted at 110 ℃ with stirring for 16 hours. The reaction mixture was added to water (100mL), ethyl acetate (200mL) was added, the mixture was stirred and separated, the aqueous phase was extracted twice with ethyl acetate (100mL), the organic phases were combined, the organic phase was washed with saturated brine (100mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo to give the crude product. The crude product is separated by silica gel column chromatography (eluent: dichloromethane: methanol: 100:0 to 10:1) and purified to obtain a compound 1-7. 1 HNMR(400MHz,DMSO-d 6 )δ8.00(br d,J=6.0Hz,1H),7.82(d,J=9.8Hz,1H),7.56(d,J=8.8Hz,2H),7.44-7.35(m,1H),7.22-7.12(m,2H),7.08-6.92(m,5H),4.74(br t,J=6.8Hz,1H),4.06-3.96(m,1H),3.94-3.82(m,2H),1.45(d,J=6.8Hz,3H),1.40(s,9H),1.15(br d,J=6.3Hz,3H);LCMS m/z=531.2[M+H] + 。
And 7: synthesis of compound WX-001 hydrochloride
Compound Nos. 1 to 7(30mg, 56.54. mu. mol,1eq) were dissolved in ethyl acetate (0.5mL), ethyl acetate hydrochloride (0.5mL,4M) was added, and the reaction was stirred at 15 ℃ for 3 hours, whereupon a precipitate was precipitated. After the supernatant of the reaction solution was removed, the remaining solid was dried in vacuo to obtain WX-001 hydrochloride as a compound. 1 HNMR(400MHz,MeOH-d 4 )δ7.76(d,J=10.0Hz,1H),7.66(br d,J=8.8Hz,2H),7.42-7.32(m,1H),7.22-7.06(m,5H),6.99(br t,J=8.4Hz,1H),4.85-4.73(m,1H),4.39-4.30(m,1H),4.20-4.10(m,1H),3.87-3.78(m,1H),1.55(d,J=7.0Hz,3H),1.50(d,J=6.8Hz,3H);LCMS m/z=431.0[M+H] + 。
Examples 2 to 8 were synthesized according to the synthesis procedure of example 1, with a-1 in step 6 being replaced with the fragments in the following table, respectively.
Example 9
Compound WX-002 hydrochloride (50mg) was dissolved in a mixed solution of MeOH (1.5mL) and AcOH (0.05mL), followed by addition of aqueous formaldehyde (27mg, 37% purity) and sodium cyanoborohydride (20.65mg), and the reaction was stirred at 15 ℃ for 2 hours. The reaction was separated by preparative HPLC (column: Welch Xtimate C18100 x 40mm x 3 um; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile](ii) a And B (acetonitrile)%, 23% -63%, 8min) to obtain the compound WX-009 trifluoroacetic acid salt. 1 H NMR(400MHz,CDCl 3 )δ:7.58(br dd,J=9.2,18.2Hz,3H),7.37-7.30(m,1H),7.15(d,J=7.8Hz,1H),7.07-6.91(m,4H),6.73(d,J=9.8Hz,1H),5.61(br d,J=5.2Hz,1H),4.79(q,J=6.4Hz,1H),4.73-4.63(m,1H),4.38-4.30(m,1H),4.10-3.95(m,1H),3.69-3.59(m,1H),3.11(s,3H),3.07-2.89(m,1H),2.50-2.09(m,4H),1.53(d,J=6.8Hz,3H);LCMS m/z=471.1[M+1] + 。
Example 10 was synthesized according to the synthetic procedure of example 9 substituting formaldehyde for acetone and example 11 was synthesized from a fragment of the compound WX-002 hydrochloride for WX-008 hydrochloride.
Example 12
Step 1: synthesis of Compound 12-2
12-1(60g,327.50mmol,1eq) and potassium carbonate (4.53g,32.75mmol,0.1eq) were dissolved in ethyl acetate (600mL), added, and cooled to-10 ℃ under an ice salt bath. NBS (64.12g,360.25mmol,1.1eq) was added portionwise, the temperature controlled below 0 ℃ and the reaction was carried out for 2 hours. NBS (5.83g,0.1eq) was added and the reaction was continued for 10 min. Using diatomite to react with the reaction solutionFiltration and the filter cake washed with a small amount of ethyl acetate. The filtrate was washed with an aqueous sodium sulfite solution (500mL), then with saturated brine (500mL), and dried over anhydrous sodium sulfate. Filtering, and vacuum concentrating the filtrate to obtain crude product. And (3) separating and purifying the crude product by silica gel column chromatography (ethyl acetate: petroleum ether is 0-50%) to obtain the crude product. The crude product is stirred and pulped by isopropyl ether (50mL) to obtain the compound 12-2. 1 H NMR(400MHz,CDCl 3 )δ:5.33(br s,2H),4.26(q,J=7.0Hz,2H),1.32(t,J=7.2Hz,3H);LCMS m/z=233.8[M+1] + 。
Step 2: synthesis of Compound 12-3
Compound 12-2(40g,170.90mmol,1eq) and potassium phosphate (54.42g,256.36mmol,1.5eq) were added to DMF (250mL), stirred for 20 minutes, then ethyl 3-ethoxyacrylate (29.57g,205.08mmol,29.63mL,1.2eq) was added and reacted at 125 ℃ for 7 hours. After cooling, water (250mL) was added to the reaction mixture, and 3M hydrochloric acid (250mL) was added with stirring to precipitate a solid, which was then filtered. And drying the filter cake in vacuum to obtain the compound 12-3. 1 H NMR(400MHz,CDCl 3 )δ:9.76(br s,1H),7.97(d,J=8.0Hz,1H),6.09(d,J=8.0Hz,1H),4.34(q,J=7.2Hz,2H),1.35(t,J=7.2Hz,3H);LCMS m/z=287.8[M+1] + 。
And step 3: synthesis of Compound 12-4
A solution of compound 12-3(2g,6.99mmol,1eq) and cuprous cyanide (1.57g,17.48mmol,3.82mL,2.5eq) in DMF (10mL) was heated to 125 ℃ and reacted with stirring for 65 hours. The cooled reaction solution was poured into water (200mL), stirred for 20 minutes, solid precipitated, filtered, and the filter cake was vacuum dried at 65 ℃ to give compound 12-4. The crude product was used in the next reaction without purification.
And 4, step 4: synthesis of Compounds 12-5
Compound 12-4(1.5g,6.46mmol,1eq), triethylamine (1.96g,19.38mmol,2.70mL,3eq) and 4-dimethylaminopyridine (157.84mg,1.29mmol,0.2eq) were added sequentially to dichloromethane (10mL), under nitrogen, and a solution of p-toluenesulfonyl chloride (3.08g,16.15mmol,2.5eq) in dichloromethane (5mL) was added slowly at 0 ℃. Slowly warmed to room temperature and 25 ℃ for 4 hours. The reaction solution was poured into water containing 25mL, and 100mL of bis (R) was added theretoChloromethane, stirring for 10 minutes, and separating. The organic and aqueous phases were then stirred for an additional 10 minutes with an additional 50mL of purified water and 50mL of methylene chloride, respectively. The liquid was separated, and all organic phases were combined, dried over anhydrous sodium sulfate, and filtered. And concentrating the filtrate in vacuum to obtain a crude product, stirring and pulping the crude product for 2.5 hours by using methanol (5mL), filtering, and drying a filter cake in vacuum to obtain a compound 12-5. 1 H NMR(400MHz,CDCl 3 )δ:8.68(d,J=7.2Hz,1H),8.36(d,J=8.0Hz,2H),7.43(d,J=8.0Hz,2H),6.87(d,J=7.6Hz,1H),4.54(q,J=7.0Hz,2H),2.48(s,3H),1.52(t,J=7.2Hz,3H);LCMS m/z=387.0[M+1] + 。
And 5: synthesis of Compounds 12-6
The compound 12-5(5g,12.94mmol,1eq) was dissolved in N-methylpyrrolidone (50mL), and N, N-diisopropylethylamine (5.02g,38.82mmol,6.76mL,3eq) and the compound (R) -1- (3-fluorophenyl) ethylamine (1.80g,12.94mmol,1eq) were added and the reaction was stirred at 80 ℃ for 16 hours. After the reaction is finished, the reaction solution is added into 150mL of water, a solid is separated out, the solid is filtered, a filter cake is washed by water, and the filter cake is dried in vacuum to obtain the compound 12-6. 1 H NMR(400MHz,DMSO-d 6 )δ:8.74(d,J=7.53Hz,1H),8.63(d,J=7.78Hz,1H),7.35-7.40(m,1H),7.27(br d,J=7.28Hz,2H),7.04-7.10(m,1H),6.62(d,J=7.78Hz,1H),5.27(q,J=7.03Hz,1H),4.22-4.33(m,2H),1.52(d,J=7.03Hz,3H),1.32(s,3H);LCMS m/z:354.1[M+1] + 。
Step 6: synthesis of Compounds 12-7
Dissolving a compound 12-6(1g,2.83mmol,1eq) in a mixed solvent of tetrahydrofuran (5mL), water (5mL) and methanol (5mL), adding lithium hydroxide monohydrate (593.80mg,14.15mmol,5eq), stirring at 25-30 ℃ for 4 hours, concentrating the reaction solution under reduced pressure, adjusting the pH of the concentrated solution to 3-4 by using 3M HCl, continuously stirring at 20-30 ℃ for 1hr, separating out a solid, filtering, rinsing the filter cake twice by using water (10mL), and drying the filter cake in vacuum to obtain the compound 12-7. 1 H NMR(400MHz,CD 3 OD)δ:8.37(br d,J=7.78Hz,1H),7.28-7.33(m,1H),7.21(br s,1H),7.19(br d,J=3.51Hz,1H),6.92-6.96(m,1H),6.54(br d,J=7.78Hz,1H),5.30-5.60(m,1H),1.56(d,J=6.78Hz,3H);LCMS m/z:326.1[M+1] + 。
And 7: synthesis of Compounds 12-8
Compound 12-7(1.2g,3.69mmol,1eq) was dissolved in DMF (10mL), followed by addition of NBS (656.57mg,3.69mmol,1eq) and sodium bicarbonate (929.69mg,11.07mmol,430.41uL,3eq) and stirring of the reaction mixture at room temperature 20 ℃ for 2 hours. 10mL of water was added to the reaction solution, and the mixture was extracted twice with 20mL of ethyl acetate. The organic phase was washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated in vacuo to give the crude product. The crude product was isolated and purified by preparative silica gel thin layer chromatography (petroleum ether: ethyl acetate 1:1) to give compound 12-8. 1 H NMR(400MHz,CDCl 3 )δ:8.15(d,J=7.53Hz,1H),7.34(dt,J=5.77,7.91Hz,1H),7.21(br d,J=7.78Hz,1H),7.12(br d,J=9.79Hz,1H),6.98(br d,J=1.76Hz,1H),6.21(d,J=7.78Hz,1H),5.50-5.25(m,1H),1.63(d,J=6.78Hz,3H);LCMS m/z:362.0[M+1] + 。
And 8: synthesis of Compounds 12-9
Dissolving compound 12-8(0.06g,166.58umol,1eq), A-1(75.42mg,199.90umol,1.2eq) in a mixed solvent of dioxane (3mL) and water (1mL), and adding [1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride dichloromethane complex (13.60mg,16.66umol,0.1eq), potassium carbonate (92.09mg,0.67mmol,4eq), stirred under nitrogen at 110 ℃ for 16 hours, and the reaction solution was directly concentrated in vacuo to give the crude product. The crude product was isolated and purified by silica gel column chromatography (ethyl acetate: petroleum ether ═ 0-30%) to give compound 12-9. LCMS M/z 553.1[ M +23 ]] + . The crude product was used in the next reaction without purification.
And step 9: synthesis of WX-012
The compound 12-9(0.015g,28.27umol,1eq) was dissolved in ethyl acetate (1mL), hydrochloric acid/ethyl acetate (4M,24 μ L,3.33eq) was added and the reaction was stirred at room temperature 25 ℃ for 2 hours, a solid precipitated from the reaction solution, filtered, and the solid was dried in vacuo to give a crude product. The crude product was subjected to preparative HPLC (column: Welch Xtimate C18100 x 40mm x 3 um; mobile phase: [ water (0.075% trifluoroacetic acid) -acetonitrile](ii) a 25% -55% of acetonitrile B and 8min) to obtain the compound WX-012 trifluoroacetate. 1 H NMR(400MHz,CD 3 OD):δ8.34(d,J=7.78Hz,1H),7.74(br d,J=8.78Hz,2H),7.31-7.41(m,1H),7.22(br d,J=7.78Hz,1H),7.14(br d,J=9.54Hz,1H),7.05(d,J=8.78Hz,2H),6.91-6.99(m,1H),6.56(d,J=7.78Hz,1H),4.97-5.14(m,1H),4.26(dd,J=3.51,10.29Hz,1H),4.06(dd,J=7.28,10.29Hz,1H),3.71-3.83(m,1H),1.55(d,J=7.03Hz,3H),1.46(d,J=6.78Hz,3H);LCMS m/z:431.2[M+1] + 。
Example 13, example 14, and example 15 were synthesized according to the synthetic procedure of example 12, substituting compound a-1 in step 8 with the fragments in the table below, respectively.
Biological test data
Experimental example 1: kinase inhibitory activity of compounds against TrkA and ROS1
The kinase inhibitory activity of the compounds against TrkA, ROS1 was tested at Reaction Biology corp. In reaction buffer (20mM hydroxyethylpiperazine ethanethiosulfonic acid (Hepes) (pH 7.5),10mM magnesium chloride (MgCl) 2 ) Ethylene glycol bisaminoethyl ether tetraacetic acid (EGTA) at 1mM, polyoxyethylene lauryl ether (Brij35) at 0.02% 0.02mg/mL BSA, sodium vanadate (Na) at 0.1mM 3 VO 4 ) 2mM Dithiothreitol (DTT), 1% DMSO) was added sequentially to a concentration of substrate, coenzyme factor, kinase and test compound (10 doses, 3-fold serial dilutions, 2% DMSO final concentration) and mixed well, the mixture was incubated at room temperature for 20 minutes, a concentration of substrate, coenzyme factor, kinase and test compound was added to the reaction mixture 33 The reaction was started with P-ATP and then incubated at room temperature for 120 minutes. Finally, the radioactivity of the reactant is detected by a filtration-binding method. The final kinase activity is expressed as the ratio of the remaining kinase activity in the test sample to that of the DMSO control. Dose-effect relationship curve fitting and IC calculation by GraphPad software 50 . The results are shown in Table 1:
table 1: median inhibitory concentration of kinase IC 50 (nM)
Test compounds | ROS1 | ROS1-G2032R | TrkA | ROS1 vs TrkA | ROS1-G2032R vs TrkA |
DS-6051b | 0.1 | 0.2 | 12.9 | 129 times of | 64.5 times of |
WX-001 hydrochloride salt | 0.3 | 0.1 | 168.0 | 560 times | 1680 times of |
The results show that: the compound shows higher kinase inhibition activity in ROS1 kinase and mutant ROS1-G2032R thereof, and the activity is equivalent to that of DS-6051 b; however, the compound of the invention has weak inhibitory activity to TrkA kinase, and shows 560-fold and 1680-fold kinase selectivity respectively, and the selectivity is obviously superior to DS-6051 b.
Experimental example 2: kinase inhibitory Activity of Compounds against ROS1-G2032R
The kinase inhibition activity test of the ROS1-G2032R is completed in Wuhan Heyan biological medicine science and technology limited company. ROS1-G2032R Kinase Enzyme System was purchased from Promega. Envision multi-label analyzer (PerkinElmer).
The experimental method comprises the following steps:
the enzyme, substrate, ATP and inhibitor were diluted with kinase buffer in the kit.
The test compounds were diluted 2-fold with a riffle to 8 th concentration, i.e. from 5 μ M to 2.25nM with a final DMSO concentration of 5%, setting up a double-well experiment. mu.L of each concentration gradient of inhibitor, 2. mu.L of ROS1-G2032R enzyme (0.66ng) were added to the plate, and after 30 minutes of reaction at 25 degrees, 2. mu.L of a mixture of substrate and ATP (10. mu.M ATP, 0.2. mu.g/. mu.L IGF1Rtide) was added, at which time the final concentration gradient of compound was 1. mu.M diluted to 0.45 nM. The reaction system was left at 25 ℃ for 120 minutes. After the reaction is finished, 5 mu L of ADP-Glo reagent is added into each hole, the reaction is continued for 40 minutes at 25 ℃,10 uL of kinase detection reagent is added into each hole after the reaction is finished, the chemiluminescence is read by a Perkinelmer Envision multi-label analyzer after the reaction is carried out for 30 minutes at 25 ℃, and the integration time is 0.5 second.
And (3) data analysis:
the original data was converted to inhibition rate, IC, using the equation (Sample-Min)/(Max-Min) × 100% 50 The values of (A) can be obtained by curve fitting of four parameters (obtained from the log (inhibitor) vs. response-Variable slope model in GraphPad Prism). Table 1 provides the enzymatic inhibitory activity of the compounds of the present invention against ROS1 (G2032R). The results are shown in Table 2:
table 2: median inhibitory concentration of kinase IC 50 (nM)
Test compounds | ROS1-G2032R |
WX-001 hydrochloride | 3.5 |
WX-002 hydrochloride | 3.5 |
WX-003 trifluoroacetic acid salt | 7.8 |
WX-004 trifluoroacetate salt | 8.4 |
WX-005 trifluoroacetic acid salt | 13.5 |
WX-006 trifluoroacetic acid salt | 19.9 |
WX-008 hydrochloride | 3.3 |
WX-009 trifluoroacetic acid salt | 5.8 |
WX-010 trifluoroacetic acid salt | 9.9 |
WX-011 trifluoroacetic acid salt | 22.0 |
WX-013 hydrochloride salt | 12.9 |
WX-014 trifluoroacetate salt | 24.9 |
WX-015 trifluoroacetic acid salt | 11.0 |
The results show that: the compound of the invention shows higher inhibitory activity on ROS1-G2032R mutant kinase.
Experimental example 3: inhibitory Activity of Compounds on cell proliferation
Adenosine Triphosphate (ATP) is an energy carrier commonly used in various life activities in nature, and is the minimum unit for energy storage and transfer. CellTiter-Glo TM The living cell detection kit adopts luciferase as a detection object, and the luciferase needs participation of ATP in the luminescence process. Adding CellTiter-Glo to cell culture medium TM The reagent is used for measuring the luminous value, the light signal is in direct proportion to the amount of ATP in the system, and the ATP is positively correlated with the number of living cells. Therefore, the proliferation of cells can be detected by detecting the ATP content using CellTiter-Glo kit. In the test, the cell lines are Ba/F3 SLC34A2-ROS1-WT, Ba/F3 SLC34A2-ROS1-G2032R, Ba/F3 CD74-ROS1-G2032R stable transgenic cell strains, and the number of cells per well is 5000.
IC 50 The determination process comprises the following steps:
1 cell culture and inoculation
a) Cells in the logarithmic growth phase were harvested and counted using a platelet counter. Cell viability was checked by trypan blue exclusion to ensure cell viability above 90%.
b) Adjusting the cell concentration; 90 μ L of cell suspension was added to 96-well plates, respectively.
c) Cells in 96-well plates were incubated at 37 ℃ with 5% CO 2 And cultured overnight under 95% humidity conditions.
2 diluting and dosing the drug
a) 10 times of drug solution is prepared, the highest concentration is 10 mu M, 9 concentrations are obtained, 3 times of dilution is carried out, 10 mu L of drug solution is added into each hole of a 96-hole plate inoculated with cells, and three multiple holes are arranged at each drug concentration.
b) The cells in the dosed 96-well plate were placed at 37 ℃ in 5% CO 2 And further cultured under 95% humidity conditions for 72 hours, after which CTG analysis was performed.
3 board is read to terminal
a) The CTG reagents were thawed and the cell plates were equilibrated to room temperature for 30 minutes.
b) An equal volume of CTG solution was added to each well.
c) Cells were lysed by shaking on an orbital shaker for 5 minutes.
d) The cell plate was left at room temperature for 20 minutes to stabilize the luminescence signal.
e) And reading the cold light value.
4 data processing
Data were analyzed using GraphPad Prism 5.0 software, fitted to the data using non-linear sigmoidal regression to derive a dose-effect curve, and IC was calculated therefrom 50 The values, data are shown in table 3.
TABLE 3 half-inhibitory concentration of cells IC 50 (nM)
"-" indicates no detection.
The results show that: the compound shows higher cell proliferation inhibition activity on ROS1 mutant cell strains Ba/F3 SLC34A2-ROS1-G2032R and Ba/F3 CD74-ROS1-G2032R, but shows lower cell proliferation inhibition activity on cell strains Ba/F3-LMNA-NTRK1, and the selectivity of the compound is obviously superior to that of DS-6051 b.
Experimental example 4: cassette pharmacokinetic testing of Compounds in mice
Purpose of the experiment: a7-9-week male CD-1 mouse is taken as a test animal, the drug concentration of the compound in plasma at different moments after single intravenous Injection (IV) and intragastric administration (PO) of the compound is determined by an LC/MS/MS method, the pharmacokinetic behavior of the compound in the mouse is researched, and the pharmacokinetic characteristic of the compound is evaluated.
Preparing the medicine: the compounds are all prepared into clear solution by using 5% DMSO, 10% solutol and 85% water as solvents, and are used for IV (intravenous injection) and PO (intragastric administration) group administration. The method of administration was cassette (cassette dosing) and the dose of each compound administered was: IV 1.0 mg/kg; PO dose was 3.0 mg/kg. Pharmacokinetic parameter results are shown in table 4:
TABLE 4 results of the cassette pharmacokinetic test in mice
The results show that: the compounds of the present invention exhibit superior pharmacokinetic properties.
Claims (13)
1. A compound represented by the formula (III) or a pharmaceutically acceptable salt thereof,
wherein, the first and the second end of the pipe are connected with each other,
y and T are each independently selected from CH and N;
R 1 selected from F, Cl, Br, I, C 1-3 Alkyl radical, C 1-3 Alkoxy, pyrrolidinyl and-C 1-3 Alkoxy-pyrrolidinyl, said C 1-3 Alkyl radical, C 1-3 Alkoxy, pyrrolidinyl and-C 1-3 Alkoxy-pyrrolidinyl is optionally substituted with 1, 2 or 3R a Substitution;
R 2 selected from F, Cl, Br, I, OH and C 1-3 Alkyl radical, said C 1-3 Alkyl is optionally substituted by 1, 2 or 3R b Substitution;
m and n are each independently selected from 1 and 2;
l is selected from-C 1-3 Alkyl-, -N (R) c )-C 1-3 alkyl-and-O-C 1-3 Alkyl-;
ring a is selected from phenyl, pyridyl, pyrimidinyl, and pyrazinyl;
ring B is selected from phenyl and pyridyl;
R a independently selected from F, Cl, Br, I, OH, NH 2 、=O、C 1-3 Alkyl and C 1-3 An alkylamino group;
R b independently selected from F, Cl, Br, I, OH and NH 2 ;
R c Selected from H and C 1-3 An alkyl group.
5. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from F, Cl, Br, I and CH 3 Said CH 3 Optionally substituted by 1, 2 or 3R b And (4) substitution.
6. A compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from F, Cl, Br, I, CH 3 And CF 3 。
7. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein L is selected from-CH 2 -、-CH 2 CH 2 -、-NH-CH 2 -、-NH-CH(CH 3 ) and-O-CH 2 -。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021102161474 | 2021-02-25 | ||
CN202110216147 | 2021-02-25 | ||
CN2021106834327 | 2021-06-18 | ||
CN202110683432 | 2021-06-18 | ||
CN2021111399725 | 2021-09-27 | ||
CN202111139972 | 2021-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114957259A true CN114957259A (en) | 2022-08-30 |
Family
ID=82975958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210164876.4A Pending CN114957259A (en) | 2021-02-25 | 2022-02-22 | Cyano-substituted aromatic bicyclic compound and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114957259A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4464372A (en) * | 1982-08-16 | 1984-08-07 | Schering Corporation | Imidazo[1,2-b]pyridazines |
US20070049591A1 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
CN104520300A (en) * | 2012-06-04 | 2015-04-15 | 第一三共株式会社 | Imidazo[1,2-b]pyridazine derivative as kinase inhibitor |
CN106164076A (en) * | 2014-03-27 | 2016-11-23 | 詹森药业有限公司 | As be replaced the 4 of ROS1 inhibitor, 5,6,7 tetrahydro-pyrazoles also [1,5 a] pyrazines derivatives and 5,6,7,8 tetrahydrochysene 4H pyrazolo [1,5 a] [Isosorbide-5-Nitrae] diazacyclo heptantriene derivants |
WO2020224626A1 (en) * | 2019-05-08 | 2020-11-12 | 浙江同源康医药股份有限公司 | Compound used as kinase inhibitor and application thereof |
-
2022
- 2022-02-22 CN CN202210164876.4A patent/CN114957259A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4464372A (en) * | 1982-08-16 | 1984-08-07 | Schering Corporation | Imidazo[1,2-b]pyridazines |
US20070049591A1 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
CN104520300A (en) * | 2012-06-04 | 2015-04-15 | 第一三共株式会社 | Imidazo[1,2-b]pyridazine derivative as kinase inhibitor |
CN106164076A (en) * | 2014-03-27 | 2016-11-23 | 詹森药业有限公司 | As be replaced the 4 of ROS1 inhibitor, 5,6,7 tetrahydro-pyrazoles also [1,5 a] pyrazines derivatives and 5,6,7,8 tetrahydrochysene 4H pyrazolo [1,5 a] [Isosorbide-5-Nitrae] diazacyclo heptantriene derivants |
WO2020224626A1 (en) * | 2019-05-08 | 2020-11-12 | 浙江同源康医药股份有限公司 | Compound used as kinase inhibitor and application thereof |
Non-Patent Citations (1)
Title |
---|
张昱 等: "靶向ROS1 酪氨酸激酶小分子抑制剂的研究进展", 沈阳药科大学学报, vol. 34, no. 3, pages 266 - 274 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2024505735A (en) | Substituted pyridazine phenolic derivatives | |
TWI758999B (en) | Thiazololactam compound as erk inhibitor and application thereof | |
WO2021129817A1 (en) | Pyrimidine-based compound having inhibitory effect of ketohexokinase (khk) | |
CN114761407B (en) | Compounds as high-selectivity ROS1 inhibitors and application thereof | |
CN114450289A (en) | Pyrazolopyridines as selective BTK kinase inhibitors | |
WO2020063965A1 (en) | Pyrazolopyrimidine derivative as selective trk inhibitor | |
CN116323579B (en) | 1H-pyrrolo [2,3-c ] pyridine compound and application thereof | |
CN114957259A (en) | Cyano-substituted aromatic bicyclic compound and application thereof | |
JP7296017B2 (en) | Compounds containing benzosultam | |
WO2022161347A1 (en) | Tricyclic compounds and use thereof | |
CN113811530B (en) | Pyrimidone compounds serving as chymase inhibitors and application thereof | |
CN114787158B (en) | Sulfonylurea ring-substituted monocyclic beta-lactam antibiotics | |
KR102668124B1 (en) | Vinyl pyridine carboxamide compounds, PD-L1 immunomodulators | |
JP7026852B2 (en) | Its use as a thiadiazole derivative and a GLS1 inhibitor | |
JP2023523830A (en) | Pyrimidine-based tricyclic compound and use thereof | |
TWI825811B (en) | Thiazololactam-spiroheterocyclic compound and application thereof | |
CN114945576B (en) | Deuterated Thienopyridines | |
WO2023241618A1 (en) | Aminopyrimidine compounds and use thereof | |
CN118271317A (en) | 1H-pyrrolo [2,3-c ] pyridine compound and application thereof | |
EA046344B1 (en) | COMPOUND AS A HIGHLY SELECTIVE ROS1 INHIBITOR AND ITS APPLICATION | |
CN115260284A (en) | Phenylpropionamides compound and application thereof | |
WO2022121900A1 (en) | Pyrrolopyridine compound and application thereof | |
CN115667258A (en) | Fluoro-pyrrolopyridine compound and application thereof | |
CN114746421A (en) | Substituted quinolinopyrrolones as ATM inhibitors and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |